Citius Pharmaceuticals (CTXR) Receivables - Other (2018)

Citius Pharmaceuticals' (CTXR) quarterly Receivables - Other came in at -$818343.0 in Q4 2018, down 200.0% on a QoQ basis from $818343.0 in Q3 2018.

Citius Pharmaceuticals (CTXR) Receivables - Other (2018) Analysis & Trends

Citius Pharmaceuticals (CTXR) has 1 years of Receivables - Other data on file, last reported at -$818343.0 in Q4 2018.

Quarterly Receivables - Other changed N/A year-over-year to -$818343.0 in Q4 2018, while the trailing twelve-month figure through Sep 2019 was -$818343.0 (down 200.0% YoY) and the FY2019 annual result came in at -$818343.0, down 200.0% from the prior year.
Receivables - Other declined to -$818343.0 in Q4 2018, from $818343.0 in the prior quarter.
In the past five years, Receivables - Other ranged from a high of $818343.0 in Q3 2018 to a low of -$818343.0 in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Citius Pharmaceuticals	15.60 Mn	15.60 Mn	1.00 Mn

Download Data